Clinico‐Epidemiological and Molecular Evidences for Reactivation of Herpesviruses in Dapsone‐Induced Hypersensitivity Reactions in Nepalese Leprosy Patients: An Observational Study
Immunity, Inflammation and Disease · 2026-02 · 14 (2)
DOI: 10.1002/iid3.70385 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 25.02.2026. Verfasst von Divya Rsjb Rana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mycobacterial Research Laboratory, Anandaban Hospital, The Leprosy Mission Nepal, Lalitpur, Bagmati Province, Nepal. Hauptthemen laut MEDLINE: Dapsone, Drug Hypersensitivity, Herpesviridae, Herpesvirus 6, Human. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Dapsone hypersensitivity (DHS) is a potentially fatal and severe cutaneous adverse reaction that occurs in patients taking dapsone. As leprosy, for which dapsone is used as part of multidrug therapy, usually occurs in countries with resource limitations, the morbidity and mortality caused by DHS are more dreadful. Herpesviruses (especially HHV‐5 and 6) are frequently associated with the etiology of drug‐induced hypersensitivity reactions, and the reactivation of these viruses coincides with the reflare of clinical symptoms even after the cessation of culprit drugs.
Methods
We reviewed the hospital charts of patients (Cohort 1) with DHS who were admitted to our hospital at the time of the DHS episode. Similarly, we examined the presence of HHV‐5 and 6 in another independent group of DHS blood samples (Cohort 2) by PCR.
Results
Seventy‐one percent (71%, 17/24) of DHS patients experienced recrudescence (reflare) of symptoms ~20 days after cessation of dapsone in Cohort 1. In Cohort 2, 39% (13/33) of blood samples from DHS patients showed the presence of at least one herpesvirus.
Conclusion
In this exploratory study, our data suggest the role of herpesviruses in the natural history of DHS and identify patterns that support future hypothesis‐driven investigations into antiviral treatment strategies for the management of DHS cases, with the potential to reduce morbidity and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mycobacterial Research Laboratory, Anandaban Hospital, The Leprosy Mission Nepal, Lalitpur, Bagmati Province, Nepal.
- Central Department of Biotechnology, Tribhuvan University, Kirtipur, Nepal.
- Anandaban Hospital, The Leprosy Mission Nepal, Lalitpur, Bagmati Province, Nepal.
ORCID-Profile: Divya Rsjb Rana
Zitieren
APA
Rana, D. R., Shakya, J., Baral, S., Shrestha, R., Koju, K., Joshi, J., Hagge, D. A., & Shah, M. (2026). Clinico‐Epidemiological and Molecular Evidences for Reactivation of Herpesviruses in Dapsone‐Induced Hypersensitivity Reactions in Nepalese Leprosy Patients: An Observational Study. Immunity, Inflammation and Disease, 14(2). https://doi.org/10.1002/iid3.70385
Vancouver
Rana DR, Shakya J, Baral S, Shrestha R, Koju K, Joshi J, et al. Clinico‐Epidemiological and Molecular Evidences for Reactivation of Herpesviruses in Dapsone‐Induced Hypersensitivity Reactions in Nepalese Leprosy Patients: An Observational Study. Immunity, Inflammation and Disease. 2026;14(2). doi:10.1002/iid3.70385
BibTeX
@article{Rana2026,
author = {Rana, Divya Rsjb and Shakya, Jivan and Baral, Suwash and Shrestha, Reejana and Koju, Kishor and Joshi, Jarina and Hagge, Deanna A and Shah, Mahesh},
title = {Clinico‐Epidemiological and Molecular Evidences for Reactivation of Herpesviruses in Dapsone‐Induced Hypersensitivity Reactions in Nepalese Leprosy Patients: An Observational Study},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/iid3.70385}
}
EUVIMED